Skip to main content
Clinical Trials/NCT00432263
NCT00432263
Withdrawn
Phase 4

Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury

Pfizer0 sitesApril 2007

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Brain Injuries
Sponsor
Pfizer
Primary Endpoint
The primary endpoint is the change from baseline in the CogState™ composite score at Week 36.
Status
Withdrawn
Last Updated
11 years ago

Overview

Brief Summary

To establish the effects of genotropin replacement in patients with severe growth hormone deficiency after traumatic brain injury on cognitive function.

Registry
clinicaltrials.gov
Start Date
April 2007
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pfizer

Eligibility Criteria

Inclusion Criteria

  • Have had a previous traumatic brain injury (more than 1 year and less than 5 years) prior to the screening visit.
  • Have an Extended Glasgow Outcome Scale (GOS-E) more than or equal to 5.

Exclusion Criteria

  • Active systemic malignancy or active intracranial tumor. A successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers.
  • Receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. Topical and inhaled corticosteroids are permitted.

Outcomes

Primary Outcomes

The primary endpoint is the change from baseline in the CogState™ composite score at Week 36.

Secondary Outcomes

  • Change CogState™ at Week 12, 24, 60 and 72. Change in lean body mass and fat mass at Week 36 and 72. Change in the Extended Glasgow Outcome Scale at week 36 and 72. Change in quality of life at week 24, 36, 60 and 72. Summary of change in cardiovascular

Similar Trials